These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 24249758)

  • 21. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.
    Yan JH; Gu WJ; Pan L
    Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 24. The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.
    Karish SB; Gagnon JM
    Ann Pharmacother; 2006 Jun; 40(6):1096-104. PubMed ID: 16735669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
    Cazzola M; Calzetta L; Rogliani P; Matera MG
    Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.
    O'Malley P
    Clin Nurse Spec; 2011; 25(4):176-7. PubMed ID: 21654371
    [No Abstract]   [Full Text] [Related]  

  • 27. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype.
    Giembycz MA; Newton R
    Clin Chest Med; 2014 Mar; 35(1):203-17. PubMed ID: 24507847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.
    Oba Y; Lone NA
    Ther Adv Respir Dis; 2013 Feb; 7(1):13-24. PubMed ID: 23197074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Novel trends in pharmacotherapy of chronic obstructive pulmonary disease--prevention of exacerbations (focus on roflumilast)].
    Sinopal'nikov AI
    Klin Med (Mosk); 2014; 92(2):57-64. PubMed ID: 25269184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials.
    Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM
    Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.
    Calverley PM; Rabe KF; Goehring UM; Kristiansen S; Fabbri LM; Martinez FJ;
    Lancet; 2009 Aug; 374(9691):685-94. PubMed ID: 19716960
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.
    Gross NJ; Giembycz MA; Rennard SI
    COPD; 2010 Apr; 7(2):141-53. PubMed ID: 20397815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits and harms of roflumilast in moderate to severe COPD.
    Yu T; Fain K; Boyd CM; Singh S; Weiss CO; Li T; Varadhan R; Puhan MA
    Thorax; 2014 Jul; 69(7):616-22. PubMed ID: 24347460
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland.
    Samyshkin Y; Schlunegger M; Haefliger S; Ledderhose S; Radford M
    Int J Chron Obstruct Pulmon Dis; 2013; 8():79-87. PubMed ID: 23386787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roflumilast: A Review in COPD.
    Garnock-Jones KP
    Drugs; 2015 Sep; 75(14):1645-56. PubMed ID: 26338438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.
    Cazzola M; Picciolo S; Matera MG
    Expert Opin Pharmacother; 2010 Feb; 11(3):441-9. PubMed ID: 20102307
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutic options in the management of COPD - focus on roflumilast.
    Antoniu SA
    Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.